Ignyte Acquisition Corp

Ignyte Acquisition — SPAC Merger (April 2022)

40 slides from Ignyte Acquisition's SPAC merger presentation, Apr 29, 2022

  1. Slide 1: Peak Bio Corporate Presentation

    —_ f PEAK BIO Peak Bio Corporate Presentation April 2022 Confidential

  2. Slide 2: Disclaimer

    Disclaimer This confidential presentation (the “presentaton’)s being delivered to you by Peak Bi the “Company") for use in connection with a proposed business combination and the offering of securities ina private placement (the "Transaction’) This presentation's for informational purposes only ands

  3. Slide 3: Disclaimer

    Disclaimer Industryand Market Data In this presentation, the Company relies on and refers to publicly available information and statistics regarding market participantsin the sectors in which the Company competes and other industry data. Any comparison of the ‘Company to the industry orto any ofits

  4. Slide 4: Risk Factors

    Risk Factors ‘The risks presented below are certain of the general risks related to the Company, IGNY and the proposed business combination (the “Business Combination”) and such lists not exhaustive. The list below has been prepared solely for the purposes of the Transaction and not for any other pu

  5. Slide 5: Risk Factors

    Risk Factors Regulatory and Compliance Risks + safety and efficacy data for our product candidates, a reference drug, or published literature does not satisfactorily demonstrate safety and efficacy to the FDA or EMEA, or if the FDA, EMEA and other regulators do not permit us to rely on the data of a

  6. Slide 6: Transaction Structure and Illustrative Pro Forma Ownership

    Transaction Structure and Illustrative Pro Forma Ownership Peak Bio Ignyte PIPE reholders SPAC Investors Peak Bio will be acquired by Ignyte Acquisition GS76'0S *26:%.0S: 29-05: Corp. (“IGNY”) | $57.5M Cash in ," Expected closing: Q3 2022 $25M PIPE Approximate post-transaction enterprise value: Proc

  7. Slide 7: Transaction Overview

    Transaction Overview Sources and Uses Sources Amount Cash Held in SPAC Trust * $ 57,500,000 PEAK Shareholder Equity Rollover? $ 180,000,000 PIPE $ 25,000,000 Total Sources $ 262,500,000 Equity Issued to Peak Bio Shareholders $ 180,000,000 Net Cash to Balance Sheet” $ 72,500,000 Transaction Costs* $

  8. Slide 8: Why We are Excited About The Ignyte / Peak Bio Merger

    Why We are Excited About The Ignyte / Peak Bio Merger Peak Bio is a vision of key pH Pharma Executives who aggressively acquired key assets and raised capital* to develop them which now will be the “backbone” of Peak Bio’s Value Proposition Experienced Management Team v Visibility on Concurrent Fina

  9. Slide 9: Led By Serial Entrepreneur / Investor Hoyoung Huh, MD, PhD

    Led By Serial Entrepreneur / Investor Hoyoung Huh, MD, PhD Bringing proven historical successes and business knowledge acquired in key therapeutic areas pH Pharma Pliant Therapeutics BridgeBio CytomX Therapeutics Geron Corporation Founder & CEO Chairman Co-Founder Former Chairman Former Chairman Pri

  10. Slide 10: Today's Presenters

    Today’s Presenters HOYOUNG HUH MD, PhD Chief Executive Officer PH pridgebio neKrar PHARMA pew BiPar, (TT y. e sea cea STEPHEN LAMOND PharmD, MBA Chief Operating Officer PHARMA GE Healthcare ZOLL, (Tia. NKR PHARMACIA Anis 4 SATYAJIT MITRA PhD Head of Oncology pH PHARMA VasGeneQ Vasgene Therapies ns P

  11. Slide 11: Investment Highlights

    Investment Highlights 2 Experienced Leadership with Led by serial entrepreneur and investor, Hoyoung Huh, M.D., Ph.D., who has had multiple successful exits Proven Track Record “4 ~~ for biotech companies through both acquisitions and public markets rs Best-in-Class NEIRRIEI oe Underserved market op

  12. Slide 12: Multiple Product Candidates and Milestones to Drive Future Value

    Multiple Product Candidates and Milestones to Drive Future Value PHP-303 5th Generation Neutrophil Elastase Inhibitor TORPEDO™ Novel ADC Platform Opportunity AATD Alpha-1 Antitrypsin Deficiency ARDS Acute Respiratory Distress ‘Syndrome ADC Targeting Trop2 ADC Target Candidate Selection Discovery wor

  13. Slide 13: wOwN

    wOwN PEAK BIO Poe US Natgetny BD Oiler Pease

  14. Slide 14: Neutrophil Elastase Inhibitor Overview and Role of PHP-303

    Neutrophil Elastase Inhibitor Overview and Role of PHP-303 ah ® -Q- 14 Overview of Neutrophil Elastase (NE) * Neutrophil Elastase (NE) is a proteolytic enzyme that is required in the inflammatory response to tissue injury * In the lungs, this leads to an increase mucus secretions and an inflammatory

  15. Slide 15: PHP-303: 5th Generation Best-In-Class NE Inhibitor

    PHP-303: 5** Generation Best-In-Class NE Inhibitor Human Alpha-1 Sivelestat Mereo Pharma Earlier Bayer Molecule BAY-678 Protease Inhibitors Sodium? Asset Supplanted by PHP-303* PHP-303 1987 1*Gen 2-4 Gen 3'4Gen Y Extensive Preclinical And CMC x Weekly Infusions # Bequires Intslons p bees | Work x Hi

  16. Slide 16: Alpha-1 Antitrypsin Deficiency (AATD) Overview

    Alpha-1 Antitrypsin Deficiency (AATD) Overview What is Alpha-1 Antitrypsin Deficiency? * AATDis a chronic, genetic orphan disease caused by mutations in gene encoding Alpha-1 Antitrypsin (AAT) * AATis a protein designed to protect tissue in the body from being attacked by its own enzymes ‘Neatrophi

  17. Slide 17: PHP-303 Addresses the Unmet Medical Need in AATD

    PHP-303 Addresses the Unmet Medical Need in AATD Demonstrated * — Clinical efforts by Bayer and now pH Pharma have both demonstrated a well-behaved molecule Safet d PK * PHP-303 is well-tolerated with no severe or dose limiting toxicities or adverse events arety an * Steady state (PK) between 11 and

  18. Slide 18: PHP-303 Phase II Readiness

    PHP-303 Phase II Readiness Clinical Work Completed clinical study data supports Phase II trial design + Bayer previously completed four clinical studies with PHP-303 (SAD, MAD and Non- cystic Fibrosis Bronchiectasis) + Renewed agreement with CRO Da * Confirmed with Irish principal investigator conti

  19. Slide 19: AATD Phase IIa Protocol and Development Pathway for PHP-303

    AATD Phase Ila Protocol and Development Pathway for PHP-303 Primary / Secondary Endpoint(s) PHP-303 PO (20 mg) QD Weeks 0-12 Change from baseline COPD 120 Patients assessment test Safety Pharmacokinetic (sputum / plasma) 60 Patients PHP-303 PO (10 mg) QD Weeks 0-12 120 Patients Lung function: FEV1,

  20. Slide 20: PHP-303 Comparison vs. Mereo

    PHP-303 Comparison vs. Mereo PHP-303s highly targeted and selective NE inhibitor showed significantly higher NE inhibition vs. Mereo (NASDAQ: MREO) at lower doses = Mereo BioPharma SS Peak Bio Originator AstraZeneca Bayer Clinical Stage | Four Phase II trials on-going (1 active; 3 recruiting) Phase

  21. Slide 21: PHP-303 Additional Targeted Indications

    PHP-303 Additional Targeted Indications Addressable Markets + $1B market opportunity expected by 2027 (Non-Covid)* ARDS = ARDS Incidence: 800K (Non-Covid) Market * High Mortality = 40%; 25 days in ICU & 47 days hospitalized Future Op} + NASH Incidence: 16M NASH | + $25B market opportunity expected b

  22. Slide 22: PHP-303 AATD and ARDS Development Pathway

    PHP-303 AATD and ARDS Development Pathway Program AATD Preclinical DoD Funded Phase Ila Study adaptive Study design under consideration 2 Inflection Points Finalize MSA/Agreements Update CTAs as needed Contract with Sites Pre-Phase tll Meeting with FDA/EMEA* P3 Interim analysis Complete animal studi

  23. Slide 23: ADC Torpedo Platform

    ADC Torpedo Platform PEAK BIO

  24. Slide 24: Antibody Drug Conjugate Overview

    Antibody Drug Conjugate Overview What Are ADCs? Why Use ADCs? = ADCs are a class of anti-cancer agents that combine selectivity haar + Chemotherapies and targeted small molecules delivered of monoclonal antibodies with the cytotoxic potential of small- Seen cuca systemically must be dosed until the

  25. Slide 25: Growing ADC Market: >$22B by 2030 with Large Deal Flow

    Growing ADC Market: >$22B by 2030 with Large Deal Flow Approved Therapies Projected Revenue: $22B+ by Strong Deal Flow Even in Early Stages of Development 0 19 ca] $2 ” , A + ADC market projected to grow > 20% over the next few years + Global Trop2 market expected to surpass $4 billion by 2026 * Key

  26. Slide 26: What Makes Peak Bio's Unique Approach to ADCs Better?

    What Makes Peak Bio’s Unique Approach to ADCs Better? Antibody + Linker + Chemotherapeutic / Toxin (Targeted CytoToxicity) © Over 90% of current ADC payloads target tubulin or DNA (Processes essential to dividing cancer cells or their DNA*) Traditional ADC © There is emerging resistance to these pay

  27. Slide 27: Our Approach: Generation of Novel Toxins

    Our Approach: Generation of Novel Toxins We Use the Following Orthogonal Mechanisms of Immune Modulation in ADCs Using Novel Toxins Spliceosome Modulation (PH1) Prevent DNA mismatch repair (PH5) } ( Immune Suppression (PH6) } Cancers carry mutations in splicing factors that As cancer cells divide ra

  28. Slide 28: PH1: Potentially Best-in-Class Payload

    PH1: Potentially Best-in-Class Payload Changed & Increased Neoepitopes* * Average expression of spliced RNA transcripts treated by PH1 vs tubulin payload DMI (Kadcyla) so Tubulin directed payload T] tf PHrreared ql Avecage Expression Average Expression * Each mark / dot represents an alternatively s

  29. Slide 29: Combining Novel Toxins with Novel Targets Leads to Novel ADCs

    ry Combining Novel Toxins with Novel Targets Leads to Novel ADCs Platform allows for multiple shots on goal and BD partnerships Step | * Clone proof-of-concept mAbs against novel and clinically validated targets Identify which payload MoA best fits a cancer + Determine which target is overexpressed

  30. Slide 30: Potentially Best-in-Class ADC Candidate Targeting Trop2

    Potentially Best-in-Class ADC Candidate Targeting Trop2 Trop2 PH1 ADC-Potent In-vitro Activity* N87 Gastric Tropabizh Clinically Validated Target (Trop2) * Superior linker stability compared to an FDA approved competitor = Superior specificity to cancer cells and unique ability to generate neoepitop

  31. Slide 31: ADC Torpedo Clinical Development Pathway

    ADC Torpedo Clinical Development Pathway pros 2022 2023, 2024 Inflection Le ; ; . Points * Manufacturing Ab * GLP Tox + result Antibody manufacturing * <= + Toxin Scale up PH1 Nad * * + IND submission IND Enabling wrap-u = Mapnene rec IE (Trop2) SMSPAP * * * * + New Cancer Indications applicable to

  32. Slide 32: Corporate Summary

    Corporate Summary PEAK BIO

  33. Slide 33: Peak Bio Milestones & Value Driving Catalysts

    Peak Bio Milestones & Value Driving Catalysts 2022 2023 2024 2025 ‘tint + Pre-Phase lll Meeting with + Phase il (EU) Data (2H) Mae ae FDA/EMEA (1H) + End of Phase Il Reg Meetings PHP-303 (AATD) f “ are + Phase Ill Adaptive Design Study (aH) + Phase Ill Continues jpdate CTAs as Needed 5 bs anereeciin

  34. Slide 34: Multiple Product Candidates and Milestones to Drive Future Value

    Multiple Product Candidates and Milestones to Drive Future Value PHP-303 5th Generation Neutrophil Elastase Inhibitor TORPEDO™ Novel ADC Platform Opnonints Gey AATD Alpha-1 Antitrypsin Deficiency ARDS Acute Respiratory Distress ‘Syndrome ADC Targeting Trop2 ADC Target Candidate Selection Discovery w

  35. Slide 35: Intellectual Property Portfolio

    Intellectual Property Portfolio PHP-303 * Patents owned by Peak Bio have coverage through 2029 Patent Family * Composition of matter has some previous use claims that will expire in 2028 Acquired from * Issued (key jurisdictions) Bayer © AU, CA, CH, GER, SP, FR, UK, KOR, JP PHP-303 * Use of an NEI i

  36. Slide 36: Cash at Closing Expected to Provide Runway Through 2024

    Cash at Closing Expected to Provide Runway Through 2024* PHP-3 Fu nding Required ~$13 million to initiate and fund a Phase II AATD Trial** ~$9 million to fund ADC toxin studies / work in lead program targeting Trop2 ADC Program ~$2-3 million to be used to conduct research and development of new ADC

  37. Slide 37: Investment Highlights

    Investment Highlights a ah © Experienced Leadership with Proven Track Record Best-In-Class NE Inhibitor* Multiple Shots-on-Goal with Near-Term Catalysts Unique Platform Technology Financed by Quality Institutional Investors Differentiated Access to Asian Markets and Large Pharma Led by serial entrep

  38. Slide 38: Appendices

    Appendices PEAK BIO

  39. Slide 39: Other Programs for Future Development

    Other Programs for Future Development We use Orthogonal Modalities to de- Existing ADC Pipeline PH1 ADC pipeline Trop2 (candidate) Her2 (POC) Others (discovery) Add Linker (PH1 Toxin) > PH1 Integrating Additional Novel Toxins PHS / PH6 ADC pipeline . . . Add Linker Discovery at linker-toxin (PH5/PH6

  40. Slide 40: Evaluation of Trop2 PH1 Potency in Multiple Cancer Types

    40 Evaluation of Trop2 PH1 Potency in Multiple Cancer Types* Trop2 PH1 Antibody Drug Conjugate Shows Nanomolar Potency In Various Indications Screening Panel Bladder Breast Esophageal Head & Neck Lung (LuAD/ Lu Sq) Lung (NSCLC) Ovarian Pancreatic Gastric Uterine CRC Skin (Epidermoid) Brain (GBM) Tot

Ignyte Acquisition — SPAC Merger (April 2022) on 6ix